Kumho HT Presents Interim Clinical Results of Dual-Action Immuno-Oncology Drug at International Conference... "Notable Differentiated Mechanism"

Kumho HT announced on the 5th that it will participate in the ESMO Asia Congress and present the interim results of the Phase 1 clinical trial of its self-developed immuno-oncology drug ‘DNP-002’. Starting from this academic conference, it is expected that Kumho HT’s collaboration with global pharmaceutical companies on ‘DNP-002’ will gain further momentum.

The ‘ESMO Asia Congress’ will be held in Singapore from the 6th to the 8th. This conference focuses on multidisciplinary oncology in the Asian region, sharing the latest cancer research results, clinical trials, and treatment strategies. It serves as a platform where oncologists, researchers, medical professionals, and industry representatives from around the world gather to exchange the latest information on various cancer types.

DNP-002 is currently undergoing a Phase 1 clinical trial at Seoul Asan Medical Center and the National Cancer Center, evaluating safety, tolerability, and optimal dosage in 36 patients with solid tumors. Although dose-limiting toxicity (DLT) was observed in subjects receiving high doses during Phase 1, the therapeutic dose that maximizes anticancer effects while minimizing side effects has already been established. Kumho HT plans to present the interim results based on related data at the conference.

DNP-002 targets the ‘CEACAM6’ protein, which is overexpressed in cancer cells and neutrophil-derived myeloid-derived suppressor cells (MDSCs), simultaneously attacking tumors and MDSCs to reactivate the patient’s immune function. Due to this mechanism, the company explains that DNP-002 is regarded as a multi-action immuno-oncology drug differentiated from existing anticancer agents.

A Kumho HT representative stated, “Since medical experts and global pharmaceutical companies from around the world will attend this conference, we plan to introduce various pipelines including DNP-002 and build a global network.” He added, “DNP-002 is expected to attract attention from global pharmaceutical companies due to its differentiated mechanism and successful interim results of the Phase 1 clinical trial.”

He continued, “Next year, we will participate in international academic conferences and various events to achieve tangible results such as joint research and technology transfer with global pharmaceutical companies.” He also added, “At the same time, we will accelerate the development of other pipelines including DNP-005 (solid tumor treatment), DNP-019 (COVID-19 treatment), DNP-007 (immunomodulator), and KHT-2031 (atopic dermatitis treatment for companion dogs).”